Albuterol Sulfate Inhalation Solution Recalled

The Ritedose Corporation is conducting a voluntary recall of 0.083% <"">Albuterol Sulfate Inhalation Solution, 3 mL (in 25, 30, and 60 unit dose vials), the U.S. Food and Drug Administration (FDA) just announced.

This product is a prescription inhalation solution, administered via nebulization, for the treatment and maintenance of acute asthma exacerbations and exercise-induced asthma in children and adults.

This product is being recalled because the 2.5 mg/3 mL single use vials are embossed with the wrong concentration of 0.5 mg/ 3 mL and, therefore, represents a potential significant health hazard. The following lot numbers manufactured by The Ritedose Corporation under NDC: 0591-3797-83, 0591-3797-30, and 0591-3797-60 are included: 0N81, 0N82, 0N83, 0N84, 0NE7, 0NE8, 0NE9, 0NF0, 0P12, 0P13, 0P46, 0P47, 0PF0, and 0S15. No other Albuterol formulations or products are included in this recall.

The product is packaged as single use unit dose vials in a protective foil overwrap packaged in a shelf carton. Only the unit dose vials are incorrectly embossed as containing 0.5 mg/3 mL. The correct concentration of 2.5 mg/3 mL is labeled on the primary foil overwrap pouches and shelf cartons. This product was distributed nationwide and in Puerto Rico.

Administration of this defective product could result in a range of potential health effects that spans from temporary and medically reversible to life threatening and fatal. There is significant concern that health professionals who read the incorrect embossed concentration may upwardly adjust the volume of product used resulting in an administered amount that is five times the recommended dose. In the hospital setting, the vials are often not accompanied by the rest of the packaging, making it more likely that such a dosing error could occur.

Significant overdosing of a patient could lead to signs and symptoms of Albuterol toxicity: Tremors, dizziness, nervousness, headache, seizures, angina, high blood pressure, low potassium levels, and rapid heart rates up to 200 beats/minute.

The Ritedose Corporation is working cooperatively with the U.S. FDA to implement a nationwide recall as quickly and efficiently as possible.

Consumers should immediately return the affected product to the place it was obtained (i.e. doctor’s office, pharmacy, etc.). Wholesalers and retailers should return the product to Total Product Destruction; Attn: RECALL; 8025 Howard Street; Spartanburg, South Carolina, 29303. The Ritedose Corporation can also be reached directly, by telephone, at 1.803.935.3995 Monday through Friday, from 8:00 a.m. to 5:00 p.m., Eastern Standard Time, or by email to

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program online, or regular mail or by fax. Online:; Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: . Mail to address on the pre-addressed form; or Fax: to 1.800.FDA.0178.

This entry was posted in Pharmaceuticals. Bookmark the permalink.

© 2005-2016 Parker Waichman LLP ®. All Rights Reserved.